Myriad Genetics
MYGN
220 hedge funds and large institutions have $2.72B invested in Myriad Genetics in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 76 increasing their positions, 86 reducing their positions, and 37 closing their positions.
28% more capital invested
Capital invested by funds: $2.12B → $2.72B (+$598M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
8% less funds holding
Funds holding: 239 → 220 (-19)
10.75% less ownership
Funds ownership: 120.73% → 109.98% (-11%)
12% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 86
35% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 37
50% less call options, than puts
Call options by funds: $9.46M | Put options by funds: $19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.3M |
| 2 |
CM
Castleark Management
Chicago,
Illinois
|
+$12.1M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$11.9M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.75M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$9.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sterling Capital Management
Charlotte,
North Carolina
|
-$52.5M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$52.2M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$36.9M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$28.5M |
| 5 |
Millennium Management
New York
|
-$24.3M |
MYGN Hedge Fund Activity: Q3 2017 in Review
220 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2017, worth a combined $2.72B — up 28% from $2.12B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of MYGN and 24 opened new positions — a net loss of 13 holders — while 86 trimmed existing stakes and 76 added.
The largest buyer was BlackRock, adding an estimated $13.3M. The largest seller was Sterling Capital Management, cutting an estimated $52.5M.
- 220 institutional investors held Myriad Genetics (MYGN) as of Q3 2017, down from 239 in Q2 2017.
- Funds reported $2.72B of Myriad Genetics stock for Q3 2017, up 28% quarter-over-quarter.
- 24 funds opened new Myriad Genetics positions in Q3 2017 and 37 closed out, a net change of -13 holders.
- The largest Myriad Genetics buyer in Q3 2017 was BlackRock, an estimated $13.3M added.
- The largest Myriad Genetics seller in Q3 2017 was Sterling Capital Management, an estimated $52.5M sold.
Based on aggregated 13F filings for Q3 2017.